The kidney is unique among the body organs in that it responds to early diabetes by growing large and increasing its function and oxygen consumption (QO2). We are drawn to understand this physiology because growth, hyperfunction, and low cortical PO2 in the early diabetic kidney predict subsequent damage and decline. For the past 15 years, we have characterized glomerular and tubular function in the early diabetic kidney with particular emphasis on how glomerular filtration and proximal reabsorption affect each other. This application is focused on the renal effects of dietary salt and of common drugs that are already in the armamentarium of diabetes care. These drugs include inhibitors of the Na-glucose cotransporter SGLT2 and agonists of the glucagon-like peptide 1 receptor (GLP-1R). SGLT2 inhibitors and GLP-1R agonists are being administered to millions of diabetic patients, and lowering of the dietary salt would apply to millions more if public health recommendations were successfully implemented. Each of these maneuvers has off-target effects on glomerular and tubular function, the nuances of which we intend to investigate. The goal is to facilitate the acquisition of medical knowledge by providing a basis in physiology for developing hypotheses that are worth bringing to clinical trials for renal protection and for providing a scientific explanation of the outcome of such trials that are already in progress. The experimental work is divided into 3 Specific Aims.
Each aim addresses the impact of dietary salt, SGLT2 blockade, and GLP-1R activation on a particular aspect of kidney physiology. The three aspects of kidney physiology are 1) proximal tubular growth and transport, 2) renal hemodynamics, and 3) renal metabolism. A network assembled from cause-effect relations among transport, hemodynamic, and metabolic variables provides insight to the organic physiology that could not be determined by studying transport, hemodynamics, and metabolism in isolation.

Public Health Relevance

SGLT2 blockers and GLP-1 receptor agonists are two new classes of anti-diabetic drugs that lower blood glucose by different mechanisms, are prescribed to millions of patients, and have off-target effects on kidney function that are only partly understood. The proposed research will investigate the effects of these drugs, and of dietary salt, on several nuances of kidney function in rats and mice with diabetes. The goal is to leverage readily available drugs and diets to reduce physical and metabolic stress on the hyper-functioning diabetic kidney, thereby protecting it from damage.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Kidney Molecular Biology and Genitourinary Organ Development (KMBD)
Program Officer
Maric-Bilkan, Christine
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Veterans Medical Research Fdn/San Diego
San Diego
United States
Zip Code
Thomson, Scott C; Vallon, Volker (2018) Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes. Curr Diab Rep 18:28
Rieg, Timo; Vallon, Volker (2018) Development of SGLT1 and SGLT2 inhibitors. Diabetologia 61:2079-2086
Layton, Anita T; Edwards, Aurélie; Vallon, Volker (2018) Renal potassium handling in rats with subtotal nephrectomy: modeling and analysis. Am J Physiol Renal Physiol 314:F643-F657
Thomson, Scott C; Kashkouli, Ali; Liu, Zhi Zhao et al. (2017) Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin. Am J Physiol Renal Physiol 313:F854-F858